Home Medicine Translation and cross-cultural adaption of an instrument measuring patient’s well-being under treatment for schizophrenia
Article
Licensed
Unlicensed Requires Authentication

Translation and cross-cultural adaption of an instrument measuring patient’s well-being under treatment for schizophrenia

  • Julaeha Julaeha ORCID logo , Umi Athiyah , Margarita Maria Maramis , Agus Sugianto and Andi Hermansyah ORCID logo EMAIL logo
Published/Copyright: June 25, 2021

Abstract

Objectives

The Subjective Well-Being under Neuroleptic (SWN) Scale is a self-rating scale measuring the well-being of patients with schizophrenia under antipsychotic drug treatment. The instrument has been globally used, with issues regarding the well-being assessment scale across different cultures, patient characteristics, and country-setting remains a controversy. This study aimed to translate and culturally adapt the SWN scale into the Indonesian version (Indonesian Modified SWN or IM-SWN) and evaluate its validity and reliability.

Methods

The SWN instrument was translated and culturally adapted following internationally accepted procedures, including forward translation, expert panel review, backward-translation, pretesting and cognitive interviewing, and psychometric analysis for the final version of the scale. The translated instrument was tested on 108 schizophrenia patients. The instrument’s validity and reliability were assessed using Pearson’s correlation and Cronbach’s Alpha coefficient. Additional analysis for the socio-demographic and psychometric properties of the patient was also conducted.

Results

The range of IM-SWN total score between 30 and 112. IM-SWN was found to have a high-reliability coefficient (0.897), and the internal consistency values of each question item ranged between 0.885 and 0.910. The results also showed a high correlation between five order factors (Physical functioning, mental functioning, self-control, emotional regulation, and social integration), with a total score of between 0.768 and 0.885.

Conclusions

This study highlighted that the IM-SWN is a valid and reliable instrument for measuring well-being among the Indonesian population with schizophrenia.


Corresponding author: Andi Hermansyah, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia, Phone: +62315933150, E-mail:

Funding source: Indonesian Endowment Fund

Funding source: Universitas Airlangga

Acknowledgments

The authors thanked the head and all staffs of the Menur National Mental Hospital Indonesia and Indonesian Community Care for Schizophrenia for providing supports and facilitating data collections. We also thanked participants of this study who have provided time and efforts for this study.

  1. Research funding: The authors thanked the Indonesian Endowment Fund for Education and Universitas Airlangga for supporting this study.

  2. Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  3. Competing interests: Authors stated no conflict of interest.

  4. Informed consent: Informed consent was obtained from all individuals included in this study.

  5. Ethical approval: Ethical approval was obtained from the Research Ethics Committee of Menur Mental Hospital Surabaya, East Java, Indonesia with number 070/7556/305/2019.

References

1. Bullinger, M, Quitmann, J. Quality of life as patient-reported outcomes: principles of assessment. Dialogues Clin Neurosci 2014;16:137–45.10.31887/DCNS.2014.16.2/mbullingerSearch in Google Scholar

2. Karow, A, Wittmann, L, Schöttle, D, Schäfer, I, Lambert, M. The assessment of quality of life in clinical practice in patients with schizophrenia. Dialogues Clin Neurosci 2014;16:185–95.10.31887/DCNS.2014.16.2/akarowSearch in Google Scholar

3. The WHOQOL Group. The world health organization quality of life assessment (WHOQOL). Soc Sci Med 1995;41:1403–9.10.1016/0277-9536(95)00112-KSearch in Google Scholar

4. Bobes, J, Garcia-Portilla, MP, Bascaran, MT, Saiz, PA, Bousoño, M. Quality of life in schizophrenic patients. Dialogues Clin Neurosci 2007;9:215–26.10.31887/DCNS.2007.9.2/jbobesSearch in Google Scholar

5. Camfield, L, Skevington, SM. On subjective well being and quality of life. J Health Psychol 2008;13:764–75.10.1177/1359105308093860Search in Google Scholar

6. Heinrichs, DH, Hanlon, TE, Carpenter, WT. The quality of life scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388–98.10.1093/schbul/10.3.388Search in Google Scholar

7. Tollefson, GD, Beasley, CM, Tran, PV, Street, JS, Krueger, JA, Tamura, RN, et al.. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatr 1997;154:457–65.10.1176/ajp.154.4.457Search in Google Scholar

8. Tran, PV, Hamilton, SH, Kuntz, AJ, Potvin, JH, Andersen, SW, Beasley, C, et al.. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997;17:400–18.10.1097/00004714-199710000-00010Search in Google Scholar

9. Hamilton, SH, Revicki, DA, Genduso, LA, Beasley, CM. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double blind trial. Neuropsychopharmacology 1998;18:41–9.10.1016/S0893-133X(97)00111-5Search in Google Scholar

10. Revicki, DA, Genduso, LA, Hamilton, SH, Ganoczy, D, Beasley, CM. Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders. Quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res 1999;8:417–26.10.1023/A:1008958925848Search in Google Scholar

11. Hamilton, SH, Edgell, ET, Revicki, DA, Breir, A. Functional outcomes in schizophrenia: a comparison of olanzapine and haloperidol in European sample. Int Clin Psychopharmacol 2000;15:245–55.10.1097/00004850-200015050-00001Search in Google Scholar

12. Gureje, O, Miles, W, Keks, N, Grainger, D, Lamber, T, McGrath, J, et al.. Olanzapine versus risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophr Res 2003;61:303–14.10.1016/S0920-9964(02)00226-8Search in Google Scholar

13. Whitty, P, Browne, S, Clarke, M, McTigue, O, Waddington, J, Kinsella, T, et al.. Systematic comparison of subjective and objective measures of quality of life at 4-year follow-up subsequent to a first episode of psychosis. J Nerv Ment Dis 2004;71:137–44.10.1097/01.nmd.0000146733.26005.bdSearch in Google Scholar

14. Naber, D. A self-rating to measure subjective effects of neuroleptic drugs. Relationships to objective psychopatology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(3 Suppl):133–8.10.1097/00004850-199509000-00017Search in Google Scholar

15. Naber, D, Moritz, S, Lambert, M, Rajonk, F, Holzbach, R, Mass, R, et al.. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res 2001;50:79–88.10.1016/S0920-9964(00)00166-3Search in Google Scholar

16. De Haan, L, Weisfelt, M, Dingemans, PMAJ, Linszen, DH, Wouters, L. Psychometric properties of the subjective well-being under neuroleptics scale and the subjective deficit syndrome scale. Psychopharmacology 2002;162:24–8.10.1007/s00213-002-1054-xSearch in Google Scholar PubMed

17. Kluge, M, Wehmeier, PM, Dittmann, RW, Langer, F, Czekalla, J, Lehmann, M, et al.. A simple switching strategy for inadequately treated patients with schizophrenia to olanzapine: changes in psychopathology and subjective well-being. Pharmacopsychiatry 2005;38:6–12.10.1055/s-2005-837764Search in Google Scholar PubMed

18. Naber, D, Riedel, M, Klimke, A, Vorbach, EU, Lambert, M, Kuhn, KU, et al.. Randomized double blind comparison of olanzapine vs clozapine on subjective well-being and clinical outcomes in patients with schizophrenia. Acta Psychiatr Scand 2005;111:106–15.10.1111/j.1600-0447.2004.00486.xSearch in Google Scholar PubMed

19. Lambert, M, Schimmelmann, BG, Naber, D, Schacht, A, Karow, A, Wagner, T, et al.. Prediction of remission as a combination of symptomatic and functional remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiatr 2006;67:1690–7.10.4088/JCP.v67n1104Search in Google Scholar

20. Vothknecht, S, Schoevers, RA, de Haan, L. Subjective well-being in schizophrenia as measured with the subjective well-being under neuroleptic treatment scale: a review. Aust N Z Collage of Psychiatr 2011;45:182–92.10.3109/00048674.2010.545984Search in Google Scholar PubMed

21. Balestrieri, M, Giaroli, G, Mazzi, M, Bellantuono, C. Performance of the Italian version of the subjective well-being under neuroleptic (SWN) scale in schizophrenic outpatients. Pharmacopsychiatry 2006;39:81–4.10.1055/s-2006-941480Search in Google Scholar

22. Siamouli, M, Moutou, K, Pantoula, E, Magiria, S, Chatzivasileiou, I, Arapidis, K, et al.. Preliminary data concerning the reliability and psychometric properties of the Greek translation of the 20-item Subjective Well-Being under Neuroleptic Treatment Scale (SWN-20). Ann Gen Psychiatr 2009;8:3.10.1186/1744-859X-8-3Search in Google Scholar

23. Pazvantoglu, O, Simsek, OF, Aydemir, O, Sarisoy, G, Korkmaz, IZ, Mor, S, et al.. Reliability and validity of subjective well-being under neuroleptics scales-short form Turkish version. Bull Clin Psychopharmacol 2012;22:235–43.10.5455/bcp.20120731082335Search in Google Scholar

24. Haring, L, Mottus, R, Jaanson, P, Pilli, R, Magi, K, Maron, E. Subjective well-being under neuroleptics scale short form (SWN-K): reliability and validity in an Estonian speaking sample. Ann Gen Psychiatr 2013;12:28.10.1186/1744-859X-12-28Search in Google Scholar

25. Sanjuan, J, Haro, JM, Maurino, J, Diez, T, Ballesteros, J. Validation of the Spanish version of the subjective well-being under neuroleptic (SWN) scale in patients with schizophrenia. Med Clin 2012;25:151–4.10.1016/S0924-9338(10)71092-0Search in Google Scholar

26. Guo, J, Zhao, Z, Ha, S. Testing the reliability and validity of Chinese version of subjective well-being under neuroleptics (SWN) short form. Med J Chin People Health 2003;15:1–2.Search in Google Scholar

27. Yoon, JS, Kook, SH, Lee, HY, Lee, C, Paik, IH. The development of a Korean modification of the scale to measure subjective well-being under neuroleptic treatment (KmSWN). J Korean Neuropsychiatr Assoc 2000;39:987–98.Search in Google Scholar

28. Wild, D, Grove, A, Martin, M, Eremenco, S, McElroy, S, Verjee-Lorenz, A, et al.. Principles of good practice for translation and cultural adaptation process for Patient-Report Outcomes (PRO) measures: report of the ISPOR task force for translation and cultural adaptation. Value Health 2005;8:94–104.10.1111/j.1524-4733.2005.04054.xSearch in Google Scholar

29. Bullinger, M. Generic quality of life assessment in psychiatry. Potentials and limitations. Eur Psychiatr 1997;12:203–9.10.1016/S0924-9338(97)89106-7Search in Google Scholar

30. Karow, A, Naber, D. Subjective well-being and quality of under atypical antipsychotic treatment. Psychopharmacol 2002;162:3–10.10.1007/s00213-002-1052-zSearch in Google Scholar PubMed

31. Lambert, M, Schimmelman, BG, Karow, A, Naber, D. Subjective well-being and initial dysphoric reaction under antipsychotic drugs-concepts, measurement and clinical relevance. Pharmacopsychiatry 2003;36:181–90.10.1055/s-2003-45128Search in Google Scholar PubMed

32. Lambert, M, Naber, D, Schacht, A, Wagner, T, Hundemer, HP, Karow, A, et al.. Rates and predictors of remission and recovery during 3 years in 392 never-treated patients with schizophrenia. Acta Psychiatr Scand 2008;118:220–9.10.1111/j.1600-0447.2008.01213.xSearch in Google Scholar PubMed

33. Lambert, M, Schimmelmann, BG, Schacht, A, Karow, A, Wagner, T, Wehmeier, PM, et al.. Long-term patterns of subjective wellbeing in schizophrenia: cluster, predictors of cluster affiliation, and relation to recovery criteria in 2842 patients followed over 3 years. Schizophr Res 2009;107:165–72.10.1016/j.schres.2008.08.035Search in Google Scholar PubMed

34. Wehmeier, PM, Kluge, M, Schneider, E, Schacht, A, Wagner, T, Schreiber, W. Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatr 2007;31:703–12.10.1016/j.pnpbp.2007.01.004Search in Google Scholar PubMed

Received: 2021-01-02
Accepted: 2021-03-08
Published Online: 2021-06-25

© 2021 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Original Articles
  3. Cost of illness of diabetes mellitus in Indonesia: a systematic review
  4. Social media health interventions to improve diabetes mellitus patient outcome: a systematic review
  5. Developing pharmacokinetics–pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients
  6. Acetylcholinesterase inhibitory activity of extract and fractions from the root of Rauvolfia serpentina(L.) Bth.ex Kurz
  7. Green tea and its active compound epigallocathechin-3-gallate (EGCG) inhibit neuronal apoptosis in a middle cerebral artery occlusion (MCAO) model
  8. The effects of quercetin on nicotine-induced reward effects in mice
  9. Resveratrol ameliorates physical and psychological stress-induced depressive-like behavior
  10. Translation and cross-cultural adaption of an instrument measuring patient’s well-being under treatment for schizophrenia
  11. Quercetin promotes behavioral recovery and biomolecular changes of melanocortin-4 receptor in mice with ischemic stroke
  12. Knowledge and attitudes of healthcare professionals on prescribing errors
  13. Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells
  14. Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins
  15. Larvicidal toxicity and parasporal inclusion of native Bacillus thuringiensis BK5.2 against Aedes aegypti
  16. Synthesis, ADMET predictions, molecular docking studies, and in-vitro anticancer activity of some benzoxazines against A549 human lung cancer cells
  17. Thymoquinone and its derivatives against breast cancer with HER2 positive: in silico studies of ADMET, docking and QSPR
  18. Assessment of patient understanding of their conventional cardiac medicines and herbal prepared/derived products: preliminary survey and interviews with selected community-dwelling elderly patients in the Philippines
  19. The development and validation of the health belief model questionnaire for measuring factors affecting adherence in the elderly with hypertension
  20. Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients
  21. Shallot skin profilling, computational evaluation of physicochemical properties, ADMET, and molecular docking of its components against P2Y12 receptor
  22. Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus
  23. Analysis of matrix metalloproteinase-9 levels among acute heart failure patients with ACE inhibitor therapy (Dr. Soetomo Regional General Hospital, Surabaya)
  24. The correlation between self-related adherence, asthma-related quality of life and control of asthma in adult patients
  25. Providing counseling through home pharmacy care (HPC) for hemodialysis patients with hypertension in lowering blood pressure
  26. Community knowledge and attitude in recognizing asthma symptoms and using medication for asthma attacks: a cross-sectional study
  27. A study of anticoagulant therapy in patients with coronary artery disease
  28. The association of FKBP5 polymorphism with asthma susceptibility in asthmatic patients
  29. Gastroprotective effect of fluvoxamine and ondansetron on stress-induced gastric ulcers in mice
  30. Osteoblast iron genes: real time PCR and microarray hybridization approach under hyperoxia
  31. Attenuation of hyperplasia in lung parenchymal and colonic epithelial cells in DMBA-induced cancer by administering Andrographis paniculata Nees extract using animal model
  32. N-nitrosodiethylamine induces inflammation of liver in mice
  33. AST/ALT levels, MDA, and liver histopathology of Echinometra mathaei ethanol extract on paracetamol-induced hepatotoxicity in rats
  34. Development, characterization, molecular docking, and in vivo skin penetration of coenzyme Q10 nanostructured lipid carriers using tristearin and stearyl alcohol for dermal delivery
  35. The effect of Camellia sinensis (green tea) with its active compound EGCG on neuronal cell necroptosis in Rattus norvegicus middle cerebral artery occlusion (MCAO) model
  36. Hepatoprotective effect of ethanolic extract of sugarcane (Saccharum officinarum Linn.) leaves
  37. Correlation between the exposure time to mobile devices and the prevalence of evaporative dry eyes as one of the symptoms of computer vision syndrome among Senior High School students in East Java, Indonesia
  38. The effect of various high-fat diet on liver histology in the development of NAFLD models in mice
  39. Fabrication and characterization of bovine hydroxyapatite-gelatin-alendronate scaffold cross-linked by glutaraldehyde for bone regeneration
  40. Health related quality of life among postmenopausal woman with hormone responsive HER2− breast cancer in Indonesia
  41. Gender differences in the blood glucose type 2 diabetes patients with combination rapid and long acting insulin therapy
  42. Correlation of dietary iron intake and serum iron with thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels in adult hyperthyroid patients
  43. The effect of pillbox use and education by pharmacist toward medication adherence in diabetes mellitus patients in a Primary Health Care Center in Mataram
  44. Variation concentration effect of propyleneglycol, glycerin, and polyethyleneglycol 400 to physical properties and dissolution rate of loratadine liquisolid tablet
  45. Role of Centella asiatica and ceramide in skin barrier improvement: a double blind clinical trial of Indonesian batik workers
  46. Secondary metabolite and antipyretic effects of Maja (Crescentia cujete L.) in fever-induced mice
  47. Hydration effect on kidney function and serum electrolyte in children with tumor lysis syndrome (TLS) and risk of TLS
  48. Drug utilization study and cost analysis of adult β-thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya
  49. The role of hyperbaric oxygen to platelet aggregation in noninsulin-dependent diabetes mellitus (NIDDM)
  50. Cocrystal formation of loratadine-succinic acid and its improved solubility
  51. The role of chondroitin sulfate to bone healing indicators and compressive strength
  52. The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice
  53. Analysis of stress ulcer prophylaxis drug regimentation in surgical patients
  54. The stability and irritability study of the chitosan–Aloe vera spray gel as wound healing
  55. Effectiveness of citicoline in pediatric patients with refractive amblyopia in Surabaya, East Java, Indonesia
  56. The thermodynamic study of p-methoxycinnamic acid inclusion complex formation, using β-cyclodextrin and hydroxypropyl-β-cyclodextrin
  57. The effect of chitosan type and drug-chitosan ratio on physical characteristics and release profile of ketoprofen microparticles prepared by spray drying
  58. The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28)
  59. Knowledge, attitudes, and practices (KAP) towards COVID-19 among university students in Pakistan: a cross-sectional study
  60. The impact of glutaraldehyde on the characteristics of bovine hydroxyapatite-gelatin based bone scaffold as gentamicin delivery system
  61. Analysis of the use of antibiotics profile and factors of surgical site infections study on digestive and oncology surgeries
  62. Second internal transcribed spacer (ITS-2) as genetic marker for molecular characterization of Sarcoptes scabiei in rabbits from several areas of East Java, Indonesia
  63. Design of gossypetin derivatives based on naturally occurring flavonoid in Hibiscus sabdariffa and the molecular docking as antibacterial agents
  64. Discovery of new targeting agents against GAPDH receptor for antituberculosis drug delivery
  65. The effect of red passion fruit (Passiflora edulis Sims.) fermentation time on its activity against Extended Strain Methicillin-Resistant (ESBL) Escherichia coli and Methicillin-Resistant Staphylococcus aureus (MRSA)
  66. Antibiotic use on acute respiratory tract infection nonpneumonia and nonspecific diarrhea in Primary Health Care Centre in Banjarbaru City, South Kalimantan, Indonesia
  67. Screening of anti-HIV activities in ethanol extract and fractions from Ficus fistulosa leaves
  68. The characteristics of lactic acid bacteria isolated from fermented food as potential probiotics
  69. Profile of gyrA gene mutation in clinical isolate of levofloxacin resistant Escherichia coli
  70. Antimicrobial activity of Centella asiatica and Gigantochloa apus
  71. Drug-related problems of antibiotic use in gastroenteritis related to patient therapy outcomes at Universitas Gadjah Mada Hospital
  72. The impact of suitability of empirical antibiotics use on therapeutic outcome of respiratory tract infection patients at inpatient wards of Universitas Gadjah Mada Academic Hospital
  73. Genetic profile mutation rpoB in clinical isolate of rifampicin-resistant Staphylococcus aureus
  74. Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy
  75. Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study
  76. Analysis of prophylactic antibiotic use and risk factor of postoperative infection in urological surgery patients
  77. Molecular docking studies of Nigella sativa L and Curcuma xanthorrhiza Roxb secondary metabolites against histamine N-methyltransferase with their ADMET prediction
  78. Prediction of compounds with antiosteoporosis activity in Chrysophyllum cainito L. leaves through in silico approach
  79. Phyllanthin and hypophyllanthin, the isolated compounds of Phyllanthus niruri inhibit protein receptor of corona virus (COVID-19) through in silico approach
  80. Cratoxylum sumatranum stem bark exhibited antimalarial activity by Lactate Dehydrogenase (LDH) assay
  81. Endophytic fungi inhabiting Physalis angulata L. plant: diversity, antioxidant, and antibacterial activities of their ethyl acetate extracts
  82. Exploration of several plants from Baung Forest on bone formation cell models
  83. In vitro antimalarial activity of Garcinia parvifolia Miq. Stem extracts and fractions on Plasmodium falciparum lactate dehydrogenase (LDH) assay
  84. Antioxidant and antiviral potency of Begonia medicinalis fractions
  85. Artocarpus sericicarpus stem bark contains antimalarial substances against Plasmodium falciparum
  86. Formulation and characterization of Eleutherine palmifolia extract-loaded self-nanoemulsifying drug delivery system (SNEDDS)
  87. Analytical method for the determination of curcumin entrapped in polymeric micellar powder using HPLC
  88. Challenges in the provision of natural medicines by community pharmacists in East Java Province, Indonesia
  89. In vitro and in silico analysis of phytochemical compounds of 96% ethanol extract of semanggi (Marsilea crenata Presl.) leaves as a bone formation agent
  90. Inhibitory activity of Urena lobata leaf extract on alpha-amylase and alpha-glucosidase: in vitro and in silico approach
  91. Case Report
  92. Effect of hydrocortisone on hypocorticolism caused by pituitary adenoma
Downloaded on 3.2.2026 from https://www.degruyterbrill.com/document/doi/10.1515/jbcpp-2021-0002/html
Scroll to top button